Linvoseltamab
Regeneron
['linvoseltamab', 'mmsm']
updated linvoseltamab data (bcma bispecific)
- effective in highly-refractory disease
- clearly better responses and durability at 200mg dose level
- ?less crs than other bsabs (but hard to know) #asco23 #mmsm 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem